Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...
The Motley Fool on MSN1d
Is Viking Therepautics a Buy Now?
Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
In a significant move within the biotech sector, Viking Therapeutics (VKTX, Financial), a renowned biotech company's, CFO ...
Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...
US stocks slumped on Monday as investors eagerly wait for the outcome of the US Presidential election on Tuesday.